header advert
Orthopaedic Proceedings Logo

Receive monthly Table of Contents alerts from Orthopaedic Proceedings

Comprehensive article alerts can be set up and managed through your account settings

View my account settings

Visit Orthopaedic Proceedings at:

Loading...

Loading...

Full Access

Hip

RESULTS OF TRABECULAR METAL AUGMENTS IN PAPROSKY 3A, 3B DEFECTS AND PELVIC DISCONTINUITY: A MULTICENTRE STUDY

The International Hip Society (IHS), London, England, September 2017



Abstract

The advent of trabecular metal (TM) augments has revolutionized the management of severe bone defects during acetabular reconstruction. The purpose of this study was to evaluate patients undergoing revision total hip arthroplasty (THA) with the use of TM augments for reconstruction of Paprosky 3A, 3B defects and defects associated with pelvic discontinuity.

A retrospective study was conducted of the cases performed at four centers between August 2007 and January 2015. Patients treated with TM augments for Paprosky 3A, 3B or chronic pelvic discontinuity were included in the study. All surgeries were performed through a posterior approach. A total of 57 patients (Male 34 (69%), Female 23(31%)), mean age 54 years (range, 28–94 years), with minimum follow up of one-year were included and evaluated using intention to treat analysis. There were 44 (77%) patients with a 3A defect, 11(19%) patients with a 3B defect (6 had an associated pelvic discontinuity), and 2 (3.5%) with a 2C defect and associated pelvic discontinuity. The mean follow-up was 37 months (range, 12–96 months). One (2%) patient died after 8 years of unrelated causes. Three (5.5%) patients had acetabular component loosening requiring revision; Two failures were (3.5%) due to aseptic loosening and one (2%) due to septic loosening. Fifty-four patients had a radiologically stable integration of the components at latest follow-up - survivorship was 94.7%.

The results of this multi-center study demonstrate encouraging short and mid-term results for the use of TM augments in the management of Grade 3A and 3B defects, and defects associated with a chronic pelvic discontinuity.


Email: